Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

New enzyme replacement therapy for the treatment of glutaric aciduria type 1 (GA-1)

May 18, 2022

Celmatix identifies AMHR2 agonist to prevent premature menopause after chemotherapy

May 16, 2022

VERVE-101 shows durable editing of PCSK9 gene; GalNAc-LNPs improve delivery of base editors

May 13, 2022

Aro's Centyrin-targeted siRNA conjugates show potential for Pompe disease

May 12, 2022

GT-02329 shows promise in in vitro and in vivo Gaucher disease models

May 12, 2022

NexImmune, Yale and JDRF partner to explore AIM nanoparticles with teplizumab for type 1 diabetes

May 11, 2022

Type 2 diabetes getting precision medicine makeover

May 11, 2022

Comparative study focuses lens of human reproductive aging

May 10, 2022

Hangzhou Zhongmei Huadong Pharmaceutical divulges GLP-1 receptor agonists

May 10, 2022

Gasherbrum Bio identifies new GLP-1 receptor agonists

May 9, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 8, 2026.
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.